PureTech Year End Update and Outlook for 2024

Strong strategic and clinical progress in 2023, with multiple catalysts expected in 2024


Launching of two new Founded Entities to advance certain programs from the Wholly Owned Pipeline


Robust...

Related Keywords

Australia ,United Kingdom ,Daphne Zohar ,Karuna Therapeutics Inc ,Oncology Congress ,Clinical Development Success ,Akili Inc ,Sonde Health Inc ,European Union ,Seaport Therapeutics Inc ,Nasdaq ,International Conference On Relapse After ,Entrega Inc ,Drug Administration ,Public Health Emergency ,Puretech Health ,Vor Biopharma Inc ,Entities Seaport Therapeutics Inc ,National Institute Of Mental Health ,Twitter ,Vedanta Biosciences Inc ,Sonde Health ,United Kingdom Financial Conduct Authority Listing ,Us Department Of Defense ,Company Wholly Owned Programs ,Gallop Oncology Inc ,Wholly Owned ,Founded Entities ,Royalty Pharma ,Wholly Owned Programs ,Wholly Owned Pipeline ,Founded Entity ,Seaport Therapeutics ,Gallop Oncology ,Consolidated Cash ,Cash Equivalents ,Short Term Investments ,Puretech Board ,Chief Executive Officer ,Announced Founded Entities ,Fragilex Associated ,Ataxia Syndrome ,Maximal Electroshock Model ,Hamilton Anxiety Rating Scale ,New Drug Application ,Prescription Drug User Fee Act ,United Kingdom Financial Conduct Authority ,Fast Track ,International Conference ,Relapse After Transplant ,Cellular Therapy ,Private Securities Litigation Reform Act ,Annual Report ,Founded Entities Seaport Therapeutics ,Karuna Therapeutics ,Vedanta Biosciences ,Vor Biopharma ,Clinical Development Success Rates ,National Institute ,Mental Health ,Enforcement Policy ,Digital Health Devices ,Treating Psychiatric Disorders During ,Coronavirus Disease ,Public Health ,Markets ,